CN111372937A - 噻吩并二氮杂卓衍生物及其应用 - Google Patents

噻吩并二氮杂卓衍生物及其应用 Download PDF

Info

Publication number
CN111372937A
CN111372937A CN201880061661.1A CN201880061661A CN111372937A CN 111372937 A CN111372937 A CN 111372937A CN 201880061661 A CN201880061661 A CN 201880061661A CN 111372937 A CN111372937 A CN 111372937A
Authority
CN
China
Prior art keywords
compound
pharmaceutically acceptable
isomer
acceptable salt
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201880061661.1A
Other languages
English (en)
Other versions
CN111372937B (zh
Inventor
沈春莉
吴成德
刘勇
龚珍
黎健
陈曙辉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CSPC Zhongqi Pharmaceutical Technology Shijiazhuang Co Ltd
Original Assignee
CSPC Zhongqi Pharmaceutical Technology Shijiazhuang Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CSPC Zhongqi Pharmaceutical Technology Shijiazhuang Co Ltd filed Critical CSPC Zhongqi Pharmaceutical Technology Shijiazhuang Co Ltd
Publication of CN111372937A publication Critical patent/CN111372937A/zh
Application granted granted Critical
Publication of CN111372937B publication Critical patent/CN111372937B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

本发明涉及一类噻吩并二氮杂卓衍生物，及其在制备治疗与BET Bromodomain抑制剂相关疾病的药物中的应用。具体涉及式（Ⅰ）、（Ⅱ）所示化合物及其药学上可接受的盐。
Figure DEST_PATH_IMAGE002

Description

PCT国内申请，说明书已公开。

Claims (23)

  1. PCT国内申请，权利要求书已公开。
CN201880061661.1A 2017-09-22 2018-09-06 噻吩并二氮杂卓衍生物及其应用 Active CN111372937B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2017108671972 2017-09-22
CN201710867197 2017-09-22
PCT/CN2018/104345 WO2019056950A1 (zh) 2017-09-22 2018-09-06 噻吩并二氮杂卓衍生物及其应用

Publications (2)

Publication Number Publication Date
CN111372937A true CN111372937A (zh) 2020-07-03
CN111372937B CN111372937B (zh) 2021-10-01

Family

ID=65810642

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880061661.1A Active CN111372937B (zh) 2017-09-22 2018-09-06 噻吩并二氮杂卓衍生物及其应用

Country Status (8)

Country Link
US (1) US11312726B2 (zh)
EP (1) EP3686204A4 (zh)
JP (1) JP7417519B2 (zh)
KR (1) KR20200058483A (zh)
CN (1) CN111372937B (zh)
AU (1) AU2018334788B2 (zh)
CA (1) CA3076759A1 (zh)
WO (1) WO2019056950A1 (zh)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113631559B (zh) * 2019-03-07 2023-05-23 南京明德新药研发有限公司 同时具有BET Bromodomain蛋白抑制和PD-L1基因调控作用的化合物
WO2020192637A1 (zh) * 2019-03-22 2020-10-01 石药集团中奇制药技术（石家庄）有限公司 固体形式的brd4抑制剂化合物及其制备方法与应用
WO2021180055A1 (zh) * 2020-03-09 2021-09-16 石药集团中奇制药技术（石家庄）有限公司 一种brd4抑制剂的用途
WO2022048685A1 (zh) * 2020-09-07 2022-03-10 南京明德新药研发有限公司 苯并四氢呋喃肟类化合物的晶型及其制备方法
WO2023113457A1 (ko) * 2021-12-14 2023-06-22 (주)프레이저테라퓨틱스 폴리유비퀴틴화에 의한 표적 단백질 또는 폴리펩티드의 분해용 신규 화합물

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5712274A (en) * 1993-09-16 1998-01-27 Yoshitomi Pharmaceutical Industries, Ltd. Thienotriazolodiazepine compounds and their pharmaceutical use
CN101910182A (zh) * 2007-12-28 2010-12-08 田边三菱制药株式会社 抗癌剂
WO2015018520A1 (en) * 2013-08-06 2015-02-12 Oncoethix Sa A bet-brd inhibitor represents a novel agent for alk positive anaplastic large cell lymphoma

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3050885B1 (en) 2009-11-05 2017-10-18 GlaxoSmithKline LLC Benzodiazepine bromodomain inhibitor
DE102011082013A1 (de) * 2011-09-01 2013-03-07 Bayer Pharma AG 6H-Thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine
EP2958923A1 (de) 2013-02-22 2015-12-30 Bayer Pharma Aktiengesellschaft 4-substituierte pyrrolo- und pyrazolo-diazepine
MX2018003030A (es) 2015-09-11 2018-04-11 Dana Farber Cancer Inst Inc Acetamida tienotriazolodiazepinas y usos de las mismas.
RU2750164C2 (ru) 2015-09-11 2021-06-22 Дана-Фарбер Кэнсер Инститьют, Инк. Цианотиенотриазолодиазепины и пути их применения

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5712274A (en) * 1993-09-16 1998-01-27 Yoshitomi Pharmaceutical Industries, Ltd. Thienotriazolodiazepine compounds and their pharmaceutical use
CN101910182A (zh) * 2007-12-28 2010-12-08 田边三菱制药株式会社 抗癌剂
WO2015018520A1 (en) * 2013-08-06 2015-02-12 Oncoethix Sa A bet-brd inhibitor represents a novel agent for alk positive anaplastic large cell lymphoma

Also Published As

Publication number Publication date
JP2020534317A (ja) 2020-11-26
AU2018334788B2 (en) 2022-11-24
EP3686204A4 (en) 2021-05-19
RU2020113587A (ru) 2021-10-25
CN111372937B (zh) 2021-10-01
RU2020113587A3 (zh) 2022-03-30
KR20200058483A (ko) 2020-05-27
WO2019056950A1 (zh) 2019-03-28
AU2018334788A1 (en) 2020-04-16
EP3686204A1 (en) 2020-07-29
US11312726B2 (en) 2022-04-26
JP7417519B2 (ja) 2024-01-18
CA3076759A1 (en) 2019-03-28
US20210017190A1 (en) 2021-01-21

Similar Documents

Publication Publication Date Title
CN111372937B (zh) 噻吩并二氮杂卓衍生物及其应用
CN110944989B (zh) 作为egfr激酶抑制剂的芳基磷氧化合物
KR102089234B1 (ko) Ask1 억제제로서의 피리딘 유도체 및 이의 제조방법과 용도
CN111372925B (zh) 作为c-MET/AXL抑制剂的尿嘧啶类化合物
CN111630046B (zh) 喹唑啉衍生物及其应用
RU2747311C2 (ru) Ингибитор CDK4/6
ES2927086T3 (es) Derivado de anillo condensado como inhibidor del receptor A2A
CN111344290A (zh) 作为Wee1抑制剂的大环类化合物及其应用
CN113874379A (zh) 作为Cdc7抑制剂的四并环类化合物
CN111556869A (zh) 作为csf-1r抑制剂的杂环化合物及其应用
CN112955453A (zh) 作为选择性Trk抑制剂的吡唑并嘧啶衍生物
CN114685602A (zh) 用作iap抑制剂的smac模拟物及其用途
RU2795005C2 (ru) Тиенодиазепиновые производные и их применение
CN113631559A (zh) 同时具有BET Bromodomain蛋白抑制和PD-L1基因调控作用的化合物
RU2773844C2 (ru) Производное пиримидинсульфамида и способ его получения, и медицинское применение
RU2773844C9 (ru) Производное пиримидинсульфамида и способ его получения, и медицинское применение
TWI690526B (zh) 羥基嘌呤類化合物及其應用
EA040849B1 (ru) Кислородсодержащее арилфосфорное соединение в качестве ингибитора киназы egfr
WO2019001461A1 (zh) Irak4抑制剂

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40026523

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant